To ascertain whether the immune population could be a direct target of VEGFR3/FLT4/CD310 inhibition, we first evaluated CD310 expression in tumor immune cells and in the bone marrow of mice bearing and non-bearing tumors. The gene discussed is FLT4; the disease is neoplasm.